Clinical Trials
12 trialsNCT02085408 2024-12-13
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00516828 2023-08-04
Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Canadian Cancer Trials Group
Phase 1/2 Completed
NCT00046930 2023-07-05
Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00840177 2023-05-03
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT00372593 2021-03-24
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
Children's Oncology Group
Phase 3 Completed
NCT00469859 2017-03-15
Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Children's Oncology Group
Phase 1/2 Completed
NCT00085709 2015-09-30
S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML
SWOG Cancer Research Network
Phase 3 Completed
NCT00049179 2015-03-06
S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT00066794 2015-03-06
S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT00052299 2012-08-27
AML-17
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00838240 2012-07-20
AML-14A
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Unknown
NCT00077116 2012-07-16
Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed